tetano
Editor, Senior Moderator
Transl Res
. 2021 Sep 18;S1931-5244(21)00243-7.
doi: 10.1016/j.trsl.2021.09.001. Online ahead of print.
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Jacob E Michalski[SUP] 1 [/SUP], Jonathan S Kurche[SUP] 2 [/SUP], David A Schwartz[SUP] 3 [/SUP]
Affiliations
Abstract
While the coronavirus disease 19 (COVID-19) pandemic has transformed the medical and scientific communites since it was first reported in late 2019, we are only beginning to understand the chronic health burdens associated with this disease. Although COVID-19 is a multi-systemic disease, the lungs are the primary source of infection and injury, resulting in pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS). Given that pulmonary fibrosis is a well-recognized sequela of ARDS, many have questioned whether COVID-19 survivors will face long-term pulmonary consequences. This review is aimed at integrating our understanding of the pathophysiologic mechanisms underlying fibroproliferative ARDS with our current knowledge of the pulmonary consequences of COVID-19 disease.
. 2021 Sep 18;S1931-5244(21)00243-7.
doi: 10.1016/j.trsl.2021.09.001. Online ahead of print.
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Jacob E Michalski[SUP] 1 [/SUP], Jonathan S Kurche[SUP] 2 [/SUP], David A Schwartz[SUP] 3 [/SUP]
Affiliations
- PMID: 34547499
- DOI: 10.1016/j.trsl.2021.09.001
Abstract
While the coronavirus disease 19 (COVID-19) pandemic has transformed the medical and scientific communites since it was first reported in late 2019, we are only beginning to understand the chronic health burdens associated with this disease. Although COVID-19 is a multi-systemic disease, the lungs are the primary source of infection and injury, resulting in pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS). Given that pulmonary fibrosis is a well-recognized sequela of ARDS, many have questioned whether COVID-19 survivors will face long-term pulmonary consequences. This review is aimed at integrating our understanding of the pathophysiologic mechanisms underlying fibroproliferative ARDS with our current knowledge of the pulmonary consequences of COVID-19 disease.